公开(公告)号：US20250059239A1

公开(公告)日：2025-02-20

申请号：US18720534

申请日：2022-12-16

Applicant: Sana Biotechnology, Inc.

Inventor： Christopher BANDORO ,  Lauren Pepper MACKENZIE ,  Jagesh Vijaykumar SHAH ,  Kyle Marvin TRUDEAU

IPC: C07K14/005 ,  C12N15/86

Abstract: Provided herein are lipid particles, such as lentiviral particles, that incorporate or are pseudotyped with a variant Nipah Virus F (NiV-F) envelope glycoprotein, and in some aspects also an attachment glycoprotein (G) protein such as a NiV-G protein or a biologically active portion or variant thereof. Also provided are polynucleotides encoding the variant NiV-F and producer cells for preparation of the lipid particles, such as lentiviral particles, containing the variant NiV-F proteins, as well as methods for preparing and using the lipid particles, such as lentiviral particles.

公开(公告)号：US12227755B2

公开(公告)日：2025-02-18

申请号：US17846817

申请日：2022-06-22

Applicant: UNIVERSITÄT ZÜRICH

Inventor： Daniel D. Pinschewer ,  Lukas Flatz ,  Andreas Bergthaler ,  Rolf Zinkernagel

IPC: C12N15/86 ,  A61K35/76 ,  A61K39/12 ,  C07K14/005 ,  C12N7/00 ,  A61K39/00

Abstract: The invention relates to an infectious arenavirus particle that is engineered to contain a genome with the ability to amplify and express its genetic information in infected cells but unable to produce further infectious progeny particles in normal, not genetically engineered cells. One or more of the four arenavirus open reading frames glycoprotein (GP), nucleoprotein (NP), matrix protein Z and RNA-dependent RNA polymerase L are removed or mutated to prevent replication in normal cells but still allowing gene expression in arenavirus vector-infected cells, and foreign genes coding for an antigen or other protein of interest or nucleic acids modulating host gene expression are expressed under control of the arenavirus promoters, internal ribosome entry sites or under control of regulatory elements that can be read by the viral RNA-dependent RNA polymerase, cellular RNA polymerase I, RNA polymerase II or RNA polymerase III. The modified arenaviruses are useful as vaccines and therapeutic agents for a variety of diseases.

公开(公告)号：US12226472B2

公开(公告)日：2025-02-18

申请号：US17421541

申请日：2019-01-15

Applicant: PULIKE BIOLOGICAL ENGINEERING, INC.

Inventor： Kegong Tian ,  Yan Xiao ,  Wenqiang Pang ,  Jinzhong Sun ,  Xuke Zhang

IPC: A61K39/135 ,  A61K39/00 ,  A61P31/14 ,  C07K14/005

Abstract: A type O foot-and-mouth disease virus-like particle antigen is provided, wherein the type O foot-and-mouth disease virus-like particle antigen is type O CATHAY topotype foot-and-mouth disease virus-like particle antigen, and the type O CATHAY topotype foot-and-mouth disease virus-like particle antigen is assembled by VP0, VP3 and VP1 antigen proteins of type O CATHAY topotype foot-and-mouth disease virus. The type O foot-and-mouth disease virus-like particle antigen has good immunogenicity. The prepared vaccine can produce complete protection against the O-type foot-and-mouth disease virus on the 14th day after immunization. The antibody titer produced is higher than that of the commercial inactivated vaccine, and the duration of immune protection can be maintained for at least 133 days. The prepared vaccine composition, preparation method and use thereof are also provided.

公开(公告)号：US20250051800A1

公开(公告)日：2025-02-13

申请号：US18915537

申请日：2024-10-15

Applicant: The Broad Institute, Inc. ,  President and Fellows of Harvard College ,  Massachusetts Institute of Technology

Inventor： Pardis Sabeti ,  Mohammadsharif Tabebordbar ,  Simon Ye

IPC: C12N15/86 ,  A61K31/7088 ,  A61K47/64 ,  A61K48/00 ,  C07K7/06 ,  C07K14/005 ,  C07K14/47 ,  C12N9/22 ,  C12N15/11

Abstract: Described herein are targeting moieties that can be capable of specifically targeting muscle cells and can include an n-mer motif. In some embodiments, the n-mer motif contains an RGD motif. Also described herein are vector systems, particles, polypeptides that can encode and/or contain one or more targeting moieties. Also described herein are methods of delivering a cargo to a cell, such as a muscle cell, using one or more of the targeting moieties described herein.

公开(公告)号：US20250042950A1

公开(公告)日：2025-02-06

申请号：US18719846

申请日：2023-02-16

Applicant: ZHEJIANG DIFFERENCE BIOLOGICAL TECHNOLOGY CO., LTD

Inventor： Ruiting CHEN ,  Huimin SUN ,  Shuihua MAO ,  Mengyun ZHOU ,  Jiasheng SONG

IPC: C07K14/005 ,  A61K39/00 ,  A61K39/215 ,  A61P31/14 ,  C12N7/00 ,  C12N15/86

Abstract: A recombinant protein for displaying an S protein of severe acute respiratory syndrome coronavirus 2 (SARS-COV-2), a recombinant virion, and a use thereof, as well as a recombinant gene expressing the S protein of the SARS-COV-2 are provided. The recombinant gene or the recombinant protein includes a sequence of an extracellular domain of the S protein of the SARS-COV-2 and sequences of a TMD and a CTD of an F protein of an avian paramyxovirus (APMV). The recombinant Newcastle disease virus (NDV) including this sequence has a strong ability to produce a neutralizing antibody. A recombinant gene or protein produced through the recombinant of a sequence encoding the extracellular domain of the S protein and sequences encoding the TMD and the CTD of the F protein of the APMV (except for NDV) has a great potential to become an excellent antigen candidate for Coronavirus Disease 2019 (COVID-19) vaccines.

公开(公告)号：US20250041402A1

公开(公告)日：2025-02-06

申请号：US18697359

申请日：2022-09-29

Applicant: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI

Inventor： Peter PALESE ,  Florian KRAMMER ,  Adolfo GARCIA-SASTRE ,  Weina SUN

IPC: A61K39/215 ,  A61K39/00 ,  A61P37/04 ,  C07K14/005 ,  C12N7/00

Abstract: Described herein are recombinant Newcastle disease viruses (“NDVs”) comprising a packaged genome, wherein the packaged genome comprises a transgene comprising a nucleotide sequence encoding a protein comprising a SARS-CoV-2 delta variant spike protein or portion thereof. Also described herein are recombinant NDVs comprising a packaged genome, wherein the packaged genome comprises a transgene encoding a chimeric F protein, wherein the chimeric F protein comprises a SARS-CoV-2 delta variant spike protein ectodomain and NDV F protein transmembrane and cytoplasmic domains. The recombinant NDVs and compositions thereof are useful for the immunizing against SARS-CoV-2 delta variant as well as the prevention of COVID-19.

公开(公告)号：US20250041399A1

公开(公告)日：2025-02-06

申请号：US18792060

申请日：2024-08-01

Applicant: VIR BIOTECHNOLOGY, INC.

Inventor： Ann M. ARVIN ,  Eric BRUENING ,  Emily MARSHALL ,  Leah B. SORIAGA

IPC: A61K39/12 ,  A61K39/00 ,  A61P31/20 ,  C07K14/005 ,  C12N7/00 ,  C12N15/86

Abstract: The disclosure relates to human papillomavirus (HPV) antigens and vectors for delivering the antigens. The disclosure also relates to immunogenic compositions comprising the same, and their uses.

公开(公告)号：US12214034B2

公开(公告)日：2025-02-04

申请号：US18329696

申请日：2023-06-06

Applicant: BAYLOR RESEARCH INSTITUTE

Inventor： Sangkon Oh ,  Sandra Zurawski ,  Gerard Zurawski

IPC: A61K39/12 ,  A61K39/395 ,  C07K14/005 ,  C07K14/025 ,  C07K16/28 ,  C12N7/00 ,  A61K39/00

Abstract: Embodiments relate to novel vaccines against human papillomavirus (HPV) and HPV-related diseases, including multiple types of cancers. The HPV vaccines are composed of anti-human dendritic cell (DC) surface receptor antibodies, including CD40, and E6/7 proteins of HPV16 and 18. The technology described is not limited to making vaccines against HPV16- and HPV18-related diseases and can be applied to making vaccines carrying E6/7 from any type of HPV. The HPV vaccines described can target DCs, major and professional antigen presenting cells (APCs), and can induce and activate potent HPV E6/7-specific and strong CD4+ and CD8+ T cell responses. The HPV vaccines can be used for the prevention of HPV infection and HPV-related diseases as well as for the treatment of HPV-related diseases, including cancers.

公开(公告)号：US20250026795A1

公开(公告)日：2025-01-23

申请号：US18714509

申请日：2022-11-30

Applicant: SHAPE THERAPEUTICS INC.

Inventor： Thomas PACKARD ,  Adrian Wrangham BRIGGS ,  David Jeffrey HUSS ,  Francois VIGNEAULT ,  Ronald James HAUSE, JR. ,  Yue JIANG ,  Kevin Christopher STEIN ,  Bora BANJANIN

IPC: C07K14/005 ,  A61K48/00 ,  A61P27/02 ,  A61P27/06 ,  A61P35/00 ,  C12N15/86

Abstract: Disclosed herein are engineered AAV VP capsid polypeptides with the ability to assemble into virus particles and having improved tissue tropism to eye tissues, for example, retinal tissues, retinal pigment epithelial cells, or photoreceptor cells. The capsids are engineered using the high throughput discovery system described herein. In certain embodiments, provided herein are recombinant adeno-associated virus (AAV) VP capsid polypeptides having at least one mutation in a 581 to 589 region of the VP capsid polypeptide, corresponding to residues 581 to residue 589 of a VP1 polypeptide of SEQ ID NO: 1.

公开(公告)号：US12202861B2

公开(公告)日：2025-01-21

申请号：US18304187

申请日：2023-04-20

Applicant: The General Hospital Corporation

Inventor： Y. Esther Tak ,  Benjamin Kleinstiver ,  J. Keith Joung

IPC: C07K14/005 ,  A61K38/00 ,  C12N9/22 ,  C12N9/52 ,  C12N15/11 ,  C12N15/62

Abstract: Drug-inducible, tunable, and multiplexable Clustered Regularly Interspaced Short Palindromic Repeats from Prevotella and Francisella 1 (Cpf1)-based activators, and methods of use thereof.